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INTRODUCTION
Infectious brain lesions include all space occupying lesions
within the cranium, secondary to an infective etiology.
They account for a small proportion of all intracranial
space occupying lesions and are a result of infections due
to various organisms. The most common organism
recovered from cultures is the bacterium Streptococcus.
However, a wide variety of other bacteria (Proteus,
Pseudomonas, Pneumococcus, Meningococcus,
Haemophilus), fungi and parasites may also cause the
disease. Fungi and parasites are especially associated
with immunocompromised patients. Toxoplasmosis and
neurocysticercosis are the commonest parasitic infections
of the CNS, with Entamoeba histolytica, Naegleria and
Acanthemoba also making a small contribution. Candida,
Aspergillus and Cryptococcus neoformans are commonest
among fungi, whereas Herpes Simplex virus and
Cytomegalovirus are the leading cause of viral abscesses.
We classify these lesions in to two broad categories;
namely suppurative space occupying lesions such as brain
abscesses, and non-suppurative space occupying lesions
such as tuberculomas and hydatid cysts (Table 1). Brain
abscesses of any etiology are neurosurgical emergencies
and require urgent and aggressive management.
Tuberculoma, hydatid cysts and similar non-suppurative
lesions on the other hand behave like brain tumors, which
can usually be investigated and the management can be
planned non-urgently. The morbidity and mortality of the
two pathologies is l ikewise dif ferent, and where
suppurative lesions follow a rapid natural course with
mostly poor outcome, non-suppurative lesions usually
carry a much slower course with fairly acceptable
outcomes.  
In this review, the authors shall be discussing the three
more common forms of infectious non-suppurative brain
lesions namely tuberculomas, aspergillomas and hydatid
cysts which, although categorized under the same class,
behave very differently and thus require unique and
specific management strategies. This part I of the article
focuses on tuberculomas; aspergillomas and hydatid cysts
will be discussed in the subsequent parts. 
TUBERCULOMAS
Intracranial tuberculomas are frequently seen in endemic
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Table 1. Proposed Classification of Infectious Brain Lesions 
Suppurative Non suppurative
Bacterial Bacterial
Acute: Streptococcus Healed suppurative lesions
species Mycobacterium tuberculosis
Staphylococcus aureus (Neurotuberculoma)
Hemophilus influenzae
Bacteroides fragilis               
Chronic: Mycobacterium
tuberculosis 
Fungal or fungus like bacteria Fungal
Aspergillus fumigatus Aspergillus fumigatus
Candida albicans (Neuroaspergilloma)
Histoplasma capsulatum Cryptococcus mucinous
Cryptococcus neoformans Pseudocysts 
Nocardia asteroids (Neurocryptococcoma)
Protozoal Helminthic
Entamoeba hystolytica Echinococcus granulosis
Toxoplasma gondii (Neurohydatidosis)
Taenia solium 
(Neurocysticercosis)
Acute suppurative infection of Viral
non suppurative lesions Herpes Simplex Virus
Cytomegalovirus
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areas.1 In these areas tuberculomas account for 5-30 %
of all intracranial space occupying lesions and due to the
high prevalence of the disease most patients are
commenced on empirical anti-tuberculous therapy based
on suggestive clinical and radiological features alone.2,3
Such an approach has been previously advocated and in
the presence of a known primary tuberculous focus,
seems reasonable. The incidence in non-endemic areas is
also on a rise due to migration of individuals from endemic
areas, as well as due to the growing population of patients
who are immunocompromised and thus more susceptible
to tuberculous infection. In endemic areas CNS
tuberculosis is considered to follow the ten percent
rule .4 There are an estimated 10 million new cases of
tuberculosis worldwide, nearly 10 % of all patients with
tuberculosis tend to have CNS involvement either as
tuberculous meningitis or as intracranial tuberculomas and
till date the reported literature suggested that the two
conditions may co-exist in up to 10 % of patients. In
endemic areas, 10 % of all intracranial space occupying
lesions are tuberculomas and the mortality of intracranial
tuberculomas has also been reported at around 10 %.
Almost 70 % of patients have multiple tuberculomas.5
Mycobacterium tuberculosis is an acid fast bacillus and an
obligate aerobe. The bacteria therefore primarily affect the
lungs but can also cause disease in almost any other
tissue of the body most commonly lymph nodes, kidneys,
brain. In our experience this miliary pattern has been
associated with worse outcomes.6 The hallmark of the
disease is the formation of granulomas which are
combination of macrophages, multinucleated giant cells,
fibroblasts and collagen deposits surrounding granular
creamy cheese like caseous necrosis which may exhibit
acid fast bacilli.4 The organism may remain dormant for
long durations but it is viable and can reactivate if the
patients’ immunity is suppressed. Small granulomas
(incipient tubercles) later coalesce to form larger
granulomas and when present in brain these are termed
as intracranial tuberculomas. Since such an inflammatory
response requires an intact immune response,
tuberculomas are more commonly seen in immune-
competent patients. The unaffected brain parenchyma
around these tuberculomas may show edema and
astrocytic proliferation.7
Tuberculomas grow slowly and displace normal brain
tissue rather than destroy it. Very large tuberculomas have
been referred to by few authors as giant
tuberculomas .8,9 Based on our own experience and
recent reports which suggest poor response of
tuberculomas larger than 4 centimeters even on prolong
periods of anti-tuberculous therapy, we propose that
tuberculomas larger than 4 centimeters in their greatest
dimension be considered giant tuberculomas . 
There appear to be no gender or age related predilections
of the disease and the mean age has been reported to be
30 years, however, they are uncommon at extremes of
age. Children present more commonly with tuberculous
meningitis or arachnoidits and hydrocephalus rather than
tuberculomas.10 At our centre, only about 30 % of
patients with tuberculomas actually have a prior history or
a history of contact with tuberculosis.6 Less than 20 %
patients with tuberculomas at our centre were found to be
immunocompromised, of which 7 % were considered
immunocompromised on the basis of pregnancy or
puerperium.6 Presentation is either due to mass effect,
associated meningitis, or seizures.6,11 A history of fever
and weight loss is strongly suggestive of an intracranial
tuberculoma, if the radiological features support the
diagnosis.12 The most common presenting features in our
published series of more than one hundred patients with
tuberculomas was fever and headaches while the
commonest signs were drowsiness and cranial nerve
palsies, especially facial and abducent nerves.13,14 More
than 70 % of patients in our series had mult iple
tuberculomas at presentation and more than 30 % of
patients had both supratentorial and infratentorial
tuberculomas, hence the clinical picture can vary greatly.6
This is in contrast to previous reports which suggest that
solitary tuberculoma is more common.6 The mean number
of lesions in our series (4.5 lesions per patient) was also
higher than in previous reports, which could be due to the
preserved immune status in majority of our patients, as it
has been reported that immunocompromised patients
may have fewer tuberculomas perhaps due to a deficient
immune response necessary for formation of
tuberculomas.6,15 Very rarely patients presenting with
signs of raised intracranial pressure may be found to have
more than a hundred lesions on imaging, a condition that
has been introduced as tuberculomatosis cerebri .5,6
Laboratory work up may be inconclusive in patients with
intracranial tuberculomas but in the presence of other
parameters may help to reach the diagnosis. Anemia and
peripheral leukocytosis may be seen in up to half of these
patients, more commonly in those with associated
systemic tuberculosis and tuberculous abscesses.6
Elevated erythrocyte sedimentation rate (ESR) in patients
with a suggestive history is considered more specific as it
is seen in more than 60% of patients.6 We do not
Table 2. AKUH Management Guidelines for Intracranial 
Tuberculomas                                               
Location Size 0-1 cm Size 1-4 cm Size >4cm (Giant)
Eloquent ATT ATT Partial excision + 
ATT
Non-Eloquent ATT ATT +/- Total excision + 
excision ATT
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Figure 1: Post contrast MRI in sagittal plane showing a
large tuberculoma in cerebellum with edema and
hydrocephalus
Figure 4: Post contrast CT scan in axial plane showing
multilobular tuberculoma involving pons and
cerebellum
Figure 5: Post contrast CT scan in axial plane showing a
tuberculoma adjacent to fourth ventricle with
hydrocephalus
Figure 3: Post contrast MRI in sagittal plane showing
multiple tubercular lesions in frontal lobe, occipital
lobe and cerebellum
Figure 2: Post contrast brain CT scan in axial plane
showing multiple enhancing lesions throughout brain,
histologically proven to be tuberculomas
            
recommend lumbar puncture in these patients but
cerebrospinal fluid (CSF) analysis may show characteristic
picture of elevated protein counts, elevated cell counts
(classically lymphocytes) and low CSF glucose levels.16
Acid fast bacteria may be noticed on staining but CSF
cultures are hardly ever positive and take six weeks for
finalization. CSF polymerase chain reaction (PCR) is
quicker, more sensitive as well as specific and should be
carr ied out routinely in endemic areas, although
availability and cost are two limitations of the test.17
Tissue cultures on the other hand are even more sensitive
than PCR.18 Whenever tissue can be acquired safely for
confirmation of diagnosis, it should be preferred.19
Histopathology, however, remains the gold standard.20
The CT appearance of tuberculoma is diverse and the
famous target sign  and calcif ication, previously
associated with tuberculomas has been rarely seen at our
centre.5,21,22 The lesion may be hyperdense due to a high
protein or calcium content, or hypodense due to necrosis.
Enhancement pattern may also be nonspecific with most
lesions showing homogenous or ring enhancement.2
Magnetic resonance appearance of tuberculoma is diverse
and relates to the histological stage of tuberculoma.23
Small lesions most commonly appear isointense on T1
weighted images and hyperintense on T2 weighted and
FLAIR images, and less commonly hypointense on T2
weighted images. As for the larger lesions, non contrast
T1 weighted images may show iso or hypointense lesion
with or without hypointense surrounding rim and non
contrast T2 weighted images may show a variety of
combinations such as a hypointense core with
hyperintense r im, hyperintense core without r im,
hyperintense core with hypointense rim.5 The pattern of
enhancement is usually the same as in CT scans i.e. it
may show homogenous, ring like, or less commonly,
lobular patterns. FLAIR images are relatively more
sensitive and show isointense or hypointense core with
hyperintense r im and surrounding edema. Core
hypointensity has been shown to correlate with necrosis
and hypercellularity. Caseous necrosis is specific for
tuberculosis and is characterized by relatively large
amount of lipid contents within the tuberculomas.5 MRI
scans are more sensitive for diagnosing accurate number
of lesions, peri lesional edema and meningeal
enhancement.24 Differential diagnosis include
metastases, high grade gliomas, neurocysticercosis,
among other enhancing lesions.15,25 (Figure 1-5) 
No other CNS infection has seen such a change in
management principles as tuberculosis.11,26,27 Initial
literature is filled with reports of successful treatments
with surgical excision of tuberculomas up to mid 1980s,
but with the introduction of better medications and with
reports of equal or even better results with anti
tuberculous therapy alone, the paradigm shifted towards
non-surgical management.28 Patients in endemic areas
were managed on the basis of clinical suspicion alone
without the need for histological diagnosis. Neurosurgical
intervention was restricted to stereotactic or CT guided
biopsies of suspect lesions or lesions not responding to
medications.20 Recent reports however suggest that
medical therapy may be insufficient for complete cure of
these lesions, with 20-46% of the lesions failing to resolve
on prolonged (18 months) of anti-tuberculous therapy
alone.11,18 
It has been recommended that medical management be
initiated for most tuberculomas which can be diagnosed
with reasonable confidence based only on their clinical
and radiological features.29,30 Whenever the diagnosis is
suspect, the choice is between an empirical course of anti
tuberculous therapy followed by repeat imaging or a biopsy
of the most superficial lesion in the least eloquent area is
recommended.2,3 For biopsy, excision of the entire
tuberculoma is always preferable if it can be done safely.3
If lesions near eloquent areas need to be biopsied,
stereotactic neuronavigation or ultrasound guided
aspirations are useful. For giant tuberculomas, or
tuberculomas not responding to therapy, or tuberculomas
causing significant mass effect, surgical excision should
be considered . When more than one lesion is present,
giant tuberculomas are excised.18 An aggressive attitude
towards these giant tuberculomas is based on our
experience that these hardly ever resolve with medical
therapy alone, require long duration of therapy, have a
high risk of reactivation and may show the paradoxical
effect. Debulking of these lesions not only reduces bulk
but also improves antibiotic penetration and lowers steroid
requirements.18 Partial excision of tuberculomas carries a
higher risk of post-operative hemorrhage. The post-
operative course is usually unremarkable. We as a policy
recommend biopsy for al l  suspected intracranial
tuberculomas prior to initiation of chemotherapy.
The standard treatment regimen is based on four drugs
which include isoniazid, rifampicin, pyrizinamide and
ethambutol or streptomycin. Isoniazid and pyrizinamide
have relatively better CSF penetration and this regimen is
equally effective for concomitant tuberculous meningitis.31
There is no consensus on the rate of resolution of
intracranial tuberculomas and consequently on optimal
duration of therapy.11,18,28,32 Recommended duration of
antituberculous therapy is at least 9 to 18 months,
depending upon the patient’s clinical and radiological
response, but may have to be continued for longer or
changed to second line medications.11,27,33,34 Sometimes
despite adequate antimicrobial coverage, the tuberculoma
may increase in size, a phenomena referred to as the
paradoxical response . This generally occurs over a
period of 1 to 3 months after the commencement of
chemotherapy.35,36 We suggest that under such
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circumstances, serious thought should be given to re-
confirmation of diagnosis and/or excision of tuberculomas.
Use of corticosteroids is reserved only for selected
patients who have significant mass effect due to peri-
lesional edema.
Sequelae of disease include re-activation tuberculosis,
drug resistance, hydrocephalus, seizures and paradoxical
response to anti tuberculous therapy.28 Serial brain
imaging is essential to determine the length of therapy.
Intracranial tuberculomas usually carry a favorable
prognosis and the predictors of poor outcome include
coma at presentation and evidence of mil iary
tuberculosis.6 Majority of patients make complete recovery
although some may have deficits. In our series which is
one of the largest published so far, the mortality was 11
%.6
This is the end of Part I which discussed Tuberculoma in
detail; in Part II we will be discussing Aspergilloma, its
etiology, signs and symptoms, diagnosis and
management. 
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